The promise and pace of cell and gene therapy innovation is hugely exciting and continues to accelerate. The nature of these advances, however, creates unique risks related to regulatory, manufacturing, valuation assessment and commercialization. The practical components of progressing cell and gene therapies to market launch and optimizing commercial success require equally innovative solutions across everything from indication selection and development strategy, to supply chain and patient access.

Navigating this complex journey through the commercial launch planning window requires early and ongoing collaboration across multiple stakeholders to ensure that these therapies are available to patients rapidly at the point of approval.

We explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene space.

Download the whitepaper